Why trust will shape the next phase of health data AI

Tern plc

Artificial intelligence is opening a significant opportunity in healthcare, but the real issue is not just technical capability. It is whether companies can turn sensitive health data into useful intelligence without creating regulatory, reputational or adoption risk.

Patient conversations, clinician notes, forums, support groups and wider lived experience often contain early signals on treatment effectiveness, side effects, adherence problems, unmet need and changing disease patterns. Traditional analytics has struggled to use this material because it is messy, context-dependent and difficult to standardise. AI is beginning to change that by turning fragmented discussion into structured insight that can be used by life sciences companies and healthcare decision-makers.

Better interpretation of real-world patient and clinician dialogue can help businesses identify safety signals earlier, understand treatment barriers, refine market strategy and improve how they prioritise development. In practical terms, that means stronger positioning, earlier signal detection and better decision-making across the product lifecycle. But that opportunity only holds if the intelligence is trusted.

In health data, weak governance is not a side issue. It can directly affect whether a company’s product is adopted, whether its data can be used with confidence and whether its operating model can scale under growing scrutiny. If an AI system introduces bias, misreads context or fails to protect privacy, the damage goes beyond compliance. It can reduce credibility with regulators, clinicians, patients and commercial partners.

Healthcare users do not need every detail of a proprietary model, but they do need to understand how data is collected, how it is processed, how conclusions are reached and how systems are validated. Clear data provenance, explainable methods, auditable model development and documented bias monitoring all help move AI from a black box to something stakeholders can rely on.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Search